Lusaris Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Lusaris Therapeutics's estimated annual revenue is currently $542.5k per year.
- Lusaris Therapeutics's estimated revenue per employee is $77,500
Employee Data
- Lusaris Therapeutics has 7 Employees.
- Lusaris Therapeutics grew their employee count by 40% last year.
Lusaris Therapeutics's People
| Name | Title | Email/Phone |
|---|
Lusaris Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Lusaris Therapeutics?
Lusaris is a biotechnology company advancing next-generation serotonergic neuroplastogen therapeutics to treat severe neuropsychiatric and neurological disorders. Our lead program, LSR-1019, is a proprietary sublingual formulation of 5-MeO-DMT, a rapidly acting and rapidly clearing serotonergic psychedelic in development for treatment-resistant depression and other neuropsychiatric conditions. In addition to LSR-1019, our pipeline includes novel neuroplastogens for a wide range of neuropsychiatric and neurological conditions including migraine and cluster headache.
keywords:N/A
N/A
Total Funding
7
Number of Employees
$542.5k
Revenue (est)
40%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Other Companies in
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $0.1M | 7 | 0% | $36M |
#2 | $0.9M | 7 | 0% | N/A |
#3 | $0.1M | 7 | 0% | $6.1M |
#4 | $0.1M | 7 | -12% | $12M |
#5 | $3.5M | 7 | -30% | N/A |